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Introduction  
 One of the most common and well-known genetic disorders is Cystic Fibrosis (CF). CF is 
a fatal autosomal recessive disorder that affects many organs including the lungs, pancreas, and 
sweat glands [1]. It is caused by a defective gene that leads to the accumulation of a thick mucus 
layer that covers the body’s airways and pancreas. This gene is known as the CFTR gene, which 
encodes for a protein called the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). 
The CFTR is a transmembrane channel located in epithelial cells that controls the movement of 
chloride and bicarbonate ions into and out of the cell. If both CFTR genes are defective, there 
will be no functioning CFTR protein, and the patient will exhibit the symptoms of CF [4]. A 
mutation within the CFTR gene can cause defects in a number of regions including synthesis, 
trafficking, stability, function, and regulation of the ion channel [5].  
 Cystic Fibrosis was not recognized as a separate disease until 1938. Before this time, it 
was grouped together with Celiac disease [6]. CF occurs in about one in 2500 Caucasian live 
births. However, this number only accounts for the defective genes found within homozygous 
individuals. Many more people are born each year who carry a single defective CFTR gene 
without even being aware of it [5]. Over the years, a greater understanding of the CFTR and CF 
as a whole has led to many promising treatments and possible cures. There is hope that as CF 
becomes more widely understood there will be a greater support from the general community, 
hopefully leading to more extensive research focused on finding a cure.  
CFTR Structure 
 The CFTR protein is a chloride channel found within the apical membrane of epithelial 
cells. CFTR is a member of the superfamily of ATP-binding-cassette (ABC) transporter proteins 
and is currently the only member known to function as an ion channel [7]. A total of 48 ABC 
transporter proteins have been discovered in the human genome to date. The ABC proteins were 
named based on the discovery that all the members of the superfamily contain two homologous 
nucleotide-binding domains (NBDs) [8]. Along with the two cytoplasmic NBDs, ABC 
transporters contain two transmembrane domains (TMDs) which are connected to the NBDs. 
Unlike other ABC transporters, the CFTR also contains a regulatory (R) domain that is found in 
between the two halves of the protein. Therefore, there are two semi-symmetrical halves on 
either side of the R domain, each containing one NBD and one TMD [3]. This gives the CFTR 
the general organization of TMD1 – NBD1 – R – TMD2 – NBD2. The TMDs each contain 6 
membrane-spanning alpha-helices, which creates a protein that crosses the membrane a total of 
12 times [2]. The general structure of CFTR can be found in figure 1.  
 
 ABC transporters are typically considered ATPases because they hydrolyze ATP in order 
to move substances against their concentration gradients. While most ABC transporters 
hydrolyze ATP at both ATP-binding sites, some, including the members of the ABCC subfamily 
of which CFTR is a part, only hydrolyze ATP at one site [8]. Within the ABCC subfamily, 
CFTR is the only ATP-gated ion channel that allows for the passive diffusion of chloride ions. 
All other members of the ABCC subfamily hydrolyze ATP in order to move large hydrophobic 
anions out of cells. Studies have shown that ABC transporters exist in two different 
Figure 1 
 
 
This image depicts the general structure of 
CFTR. There are two TMDs with six 
membrane-spanning domains each. The 
regulatory (R) domain is located in the 
center of the protein, and there are two 
NBDs.  
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conformations. For the ABC transporters, including CFTR, that export molecules from cells, the 
substrate-binding site on the TMDs is open to the cytoplasmic side of the plasma membrane 
when ATP is absent. On the other hand, when ATP binds, dimerization of the NBDs occurs 
along with a conformation change within the TMDs. This leads to the opening of the substrate-
binding site to the extracellular side of the membrane [3].  
 The R domain of the CFTR separates the NBD1 and TMD2 (fig.1). This domain seems to 
be unstructured, but it can be distinguished by a set of phosphorylation sites that are highly 
conserved. The R domain contains 200 residues and is the least conserved region within the 
entire CFTR protein sequence. However, the positions of the phosphorylation sites and the 
pattern of order-disorder within the protein sequence seem to be highly conserved. This proves 
that the R domain is functionally significant within the CFTR [8].  
 Since the CFTR protein is an ion channel, it must contain a pore somewhere within its 
structure. However, only a few studies have been carried out to determine the residues involved 
in the anion pore. Therefore, there is still uncertainty about what residues play an important role 
in this structural unit. Most research has been focused on the sixth membrane-spanning helix in 
TMD1. The cytosolic process of this structure connects TMD1 with NBD1. Since the CFTR has 
an anion-selective pore, it is predicted that the sixth membrane-spanning helix contains at least 
three basic residues. Arg 334 and Lys 335 are found towards the extracellular end while Arg 347 
is found about four helical turns away closer to the cytoplasmic end. The Arg 347 makes a salt 
bridge with an Asp found in the membrane-spanning helix 8. The positive charges on both Arg 
334 and Lys 335 aid in the entry of anions into the CFTR pore. The CFTR pore selects poorly 
among small anions. This implies that the CFTR pore is relatively featureless and has no region 
that makes an intimate contact with the chloride ions [2].  
CFTR Function and Regulation 
 As stated before, the CFTR protein is the only member of the ABC transporter 
superfamily to function as an ion channel and helps to mediate the anion conductance across 
epithelial membranes. This channel is required for both the absorption and secretion of chloride 
ions. The CFTR also functions to move bicarbonate across epithelial membrane in both 
directions both by transporting bicarbonate itself and by stimulating other chloride-bicarbonate 
exchangers. Although both chloride and bicarbonate flow through the CFTR based on their 
concentration gradients, CFTR is considered an active transporter because it requires ATP 
hydrolysis to regulate the opening of the channel [8]. The function of the CFTR as an ion 
channels has sparked a popular theory as to why CF is so prevalent in the human population. 
According to this theory, CFTR mutations became prevalent because those who had one mutated 
CFTR gene had a greater chance of escaping death from the hands of Cholera. Decreased CFTR 
channel activity reduces diarrhea by retaining chloride (this works) in the epithelial cells 
surrounding intestinal cavities. Therefore, since people with the CFTR gene had a selective 
advantage, the defective gene was passed on leading to the prevalence of CF [9]. 
  Knowing the overall function of the CFTR, the next question is how the CFTR protein 
carries out this function. The CFTR has ATP-binding sites on both of its NBDs. When ATP 
binds to both of these sites, the CFTR channel opens. However, unlike other classic ligand-gated 
ion channels, the ATP used by the CFTR is consumed in order to close the channel (fig. 2). Also, 
unlike many other ABC transporters, only one NBD of the CFTR hydrolyzes ATP. The NBD1 
domain is degenerated and has many substitutions that render it incapable of hydrolyzing ATP 
though the ATP can still bind to it. While ATP gates the CFTR channel, it cannot carry out this 
job effectively without the help of a magnesium ion. Therefore, ATP does not bind to the CFTR, 
MgATP does. The magnesium helps ATP bind to CFTR by interacting with an Asp residue. The 
magnesium is also essential for the hydrolysis of ATP which drives the closure of the CFTR gate 
[3].  
 
 It is clear that ATP binding and hydrolysis is important for the opening and closing of the 
CFTR gate, but the mystery is how this occurs. It has been found that conformation changes 
within the NBDs are coupled with conformational changes within the membrane-spanning 
domains. These conformational changes shift the equilibrium between an open and closed CFTR 
pore [8]. Evidence has been found that the binding of ATP to CFTR leads to the formation of a 
NBD dimer. This dimer formation is then linked with the opening of the CFTR gate. It was then 
Figure 2 
 
This figure shows the hypothesized ATP-dependent gating cycle of CFTR. In the figure, the 
green shape is NBD1 and the blue shape is NBD2. Initially, the CFTR channel is closed. 
However, once ATP binds to both NBDs, the channel opens. When ATP is hydrolyzed by 
NBD2, the channel reverts back to a closed state. This is a simplified diagram that does not 
show the full details of CFTR gating cycle. A more detailed diagram would show that when 
ATP is absent, the substrate-binding site is open to the cytoplasmic side of the plasma 
membrane instead of the entire channel being closed. When ATP is bound to both NBDs, the 
substrate-binding site is also open to the extracellular side of the membrane fully opening the 
channel. 
 
[2] 
hypothesized that that hydrolysis of ATP would lead to the dissociation of the dimer and 
therefore the closing of the gate [10].  
 Although this theory was popular, there has been recent evidence that disproves it. A new 
theory hypothesizes that there are both two open and two closed states for the CFTR gate. This 
was shown by the fact that the CFTR gate remains open for varying amounts of time depending 
on when pyrophosphate (PPi) is applied after the removal of ATP. When PPi is applied right 
after the removal of ATP, the channel stays open for approximately 30 seconds. However, if PPi 
is applied several minutes after the removal of ATP, the gate will only stay open for 1.5 seconds 
[11]. In this new theory, when the ATP bound to NBD2 is hydrolyzed, the CFTR channel closes 
into a partial dimer where the NBD remains partially closed. This prevents ATP from 
dissociating from NBD1 but allows the small anions to flow through the channel and a new ATP 
molecule to bind to NBD2. Based on this theory, the opening and closing of the CFTR gate is 
regulated by the formation of a NBD dimer and the partial separation of this dimer [12].  
 The gating of the CFTR protein is also regulated by phosphorylation of the R domain by 
protein kinase A (PKA). As mentioned earlier, the R domain contains approximately 200 
residues and connects the NBD1 and TMD2. Within the R domain, there are multiple sites for 
phosphorylation by PKA. So far, six sites have been found in CFTR in living cells while eight 
have been found in isolated CFTR [2]. PKA phosphorylation of CFTR is the best understood 
mechanism of regulation for the CFTR channel. However, other mechanisms of regulation have 
been discovered that are less understood. For example, it has been found that protein kinase C 
increases CFTR activity while AMP kinase inhibits CFTR. Since these mechanisms are not well 
understood at this time, I will focus on regulation by PKA [3].  
 CFTR channels that are unphosphorylated typically are less active than channels that 
have been phosphorylated. The consensus theory is that an unphosphorylated R domain inhibits 
the opening of the CFTR channel, while phosphorylation of the R domain relieves this inhibitory 
effect and allows the channel to open [3]. Currently, the mechanism for how phosphorylation of 
the R domain controls channel gating is not understood. There are no other ABC proteins that 
have R domains, and the R domain of CFTR does not show any homology to other proteins. 
Therefore, there is no previous knowledge to be drawn from in order to understand the 
mechanism of regulation. Also, the conformation of the R domain and its location within the 
CFTR channel are currently unknown [2]. 
 There are three main proposed mechanisms for the regulation of CFTR by PKA. Since 
there are multiple PKA sites in the CFTR, these mechanisms are not mutually exclusive. The 
first proposed mechanism is that the phosphorylation of the R domain regulates NBD 
dimerization [3]. It was found that split CFTR proteins could be cross-linked together at the 
NBD areas by adding cysteine amino acids to the dimer interface. Subsequently, it was 
discovered that PKA phosphorylation enhanced the efficiency of this cross-linking [13]. Another 
study supported this mechanism by structurally analyzing a fragment of the R domain of CFTR 
with NMR. The R domain fragment bound to NBD1 with most of the contact areas found near 
known PKA sites. The phosphorylation of this fragment decreased its ability to bind to NBD1. It 
was then proposed that CFTR function is inhibited when the R domain is unphosphorylated 
because it binds to the NBD1. This could in turn prevent the formation of the NBD dimer. The 
phosphorylation of the R domain would relieve this inhibition by reducing the affinity for NBD1, 
therefore allowing NBD dimer formation and opening of the CFTR channel [14].  
 The second proposed mechanism argues that the R domain also regulates CFTR channel 
function independently of the NBD dimerization. This regulation is thought to occur from 
physical interactions between the R domain, the TMDs, and their extensions within the 
cytoplasm. For example, it is thought that parts of the R domain interact with the cytosolic loops 
of CFTR when phosphorylated. This interaction then affects the conformation changes within the 
cytosolic loops that underlie CFTR gating.  
 The third mechanism proposes that phosphorylation of PKA sites in NBD1 affects the 
interactions between NBD1 and TMD. Although most PKA sites are found within the R domain, 
at least two other sites have been located within the NBD1. These regions within the NBD1 are 
called the regulatory extension and the regulatory insertion [3]. It was found that interactions 
between these specific regions and NBD1 are inhibited by phosphorylation. A binding 
interaction was also discovered between NBD1 and a peptide that only occurs when the regions 
in NBD1 are phosphorylated. It is thought that this peptide mediates the coupling of NBD1 and 
TMD1 [15]. From these three proposed mechanisms of regulation, it can be seen that there likely 
are multiple ways that PKA phosphorylation affects CFTR channel regulation.  
CFTR Synthesis and Trafficking  
 The CFTR gene has approximately 180,000 base pairs that can be found on the long arm 
of chromosome 7. This gene encodes the 1,480 amino acids that make up the CFTR. In order for 
CFTR to function properly, it must be correctly synthesized, folded, and transported to the apical 
membrane of the cell. This path from the nucleus to the plasma membrane requires many 
proteins found in different compartments throughout the pathway. Along the way, the CFTR 
protein must pass stringent quality control which weeds out any misfolded protein that could 
cause damage to the cell or simply fail to function properly [16]. There are also quality control 
systems that function throughout the life of the CFTR in order to remove proteins that might 
become damaged. All of these quality control systems function for membrane and secretory 
proteins. However, it has become apparent that the CFTR protein has more difficulty than other 
proteins in passing these rigorous tests and leaving the endoplasmic reticulum (ER). For 
example, other ABC transporters such as P-glycoprotein and MRP1 are able to mature and leave 
the ER at close to 100% efficiency. On the other hand, only approximately 33% of CFTR folds 
correctly and is allowed to leave the ER [8].  
 The first step in creating a fully functioning CFTR begins within the nucleus, where the 
CFTR gene is transcribed into mRNA. Once transcription is complete, the mRNA leaves the 
nucleus and travels to a ribosome which attaches to the ER. When the mRNA docks on the 
ribosome, tRNA carries amino acids to the ribosome and allows for the translation of CFTR [16]. 
While the polypeptide is being translated, it is also being pushed into the ER through a pore 
called the translocon. When the ribosome docks onto a translocon, it becomes known as 
ribosome-translocon complex (RTC). The RTC functions to synthesize, fold, orient and integrate 
the transmembrane (TM) sections of the CFTR into the membrane of the ER. The function of the 
RTC is controlled by specific sequences within the nascent polypeptide chain that is being 
translated [17].  
 While the CFTR polypeptide chain is being translated, it is actively being folded. CFTR 
is a membrane protein containing both membrane and cytosolic domains. The folding process for 
CFTR is complex because both the membrane and cytosolic domains must be correctly 
incorporated in order for the protein to function properly. This complex process follows two 
general sets of folding rules. The first rule is based on the hydrophobic effect. Within the cytosol 
of the cell, nonpolar residues are pushed towards the interior of the protein while the polar 
residues are left on the outside of the protein. The second rule dictates the folding of proteins 
within the bilayer of the ER where the hydrophobic effect is virtually absent. This folding 
process is based on two main steps. First, polypeptide segments of 18-25 residues that are 
sufficiently hydrophobic are inserted into the ER membrane. Once these segments are in the 
membrane, they fold into a more stable TM alpha-helix. By folding into an alpha-helix, the free 
energy needed to bury the polar residues is minimized. The second step of this process is further 
folding. The various alpha-helices bind to each other in order to adopt a tertiary and/or 
quaternary structure [5].   
 While the CFTR is folding within in the ER, it receives help from proteins known as 
chaperones. The chaperones are important for the correct folding of CFTR and preventing 
aggregation [5]. The first and most important cytosolic chaperone found to complex with CFTR 
was Hsp70 [18]. The Hsp70 chaperone works alongside other chaperones and co-chaperones to 
assist in the correct folding of CFTR. For example, a co-chaperone known as Hdj-2 helps to 
reduce aggregation during the early stages of CFTR assembly possibly by recruiting Hsc70 [8]. 
Another major chaperone detected early on was calnexin [19]. Calnexin is located within the ER 
and has both a luminal lectin domain and a polypeptide-binding site. These two areas allow 
calnexin to interact with the immature CFTR and aid in its proper folding. It is thought that 
chaperones detect any exposed hydrophobic regions located on the outside of the protein [5].  
 After folding in the ER, the CFTR must pass through a quality control system known as 
the endoplasmic reticulum-associated degradation (ERAD) process. ERAD for CFTR typically 
involves the ubiquitin proteasome system (UPS) for which CFTR is a substrate [16]. In this 
system, misfolded proteins are polyubiquitylated and degraded by a proteasome. Ubiquitin is a 
small protein made up of 76 amino acids. If a protein is targeted for degradation, ubiquitin 
covalently attaches to lysine residues on the CFTR. Ubiquitylation requires three types of 
enzymes which are the E1 ubiquitin activating enzymes, the E2 ubiquitin conjugating enzymes, 
and the E3 ubiquitin protein ligases. The ubiquitylation process begins with the activation of E1 
through hydrolysis of ATP. This creates an activated ubiquitin which is then transferred to an E2 
active site. An E3 ligase then covalently binds the activated ubiquitin to a lysine on the protein. 
Further ubiquitin molecules can then be linked together to form a polyubiquitin chain. Once the 
misfolded CFTR has been polyubiquitylated, it is removed from the ER membrane and targeted 
for degradation by the 26S proteasome in the cytoplasm. The CFTR must have at least four 
ubiquitin molecules in order to be degraded [20].  
 Misfolded CFTR proteins are detected by two separate systems during the folding 
process. One system detects defects in the cytosolic parts of the CFTR while the other system 
detects defects within the ER membrane. Ubiquitylating proteins seem to work with specific 
factors to detect misfolding such as the Hsp70 in the cytosol and Derlin-1 within the ER 
membrane. Hsp 70 detects mutations within the cytosolic region including the NBD1, NBD2, 
and R domain. It is currently thought that Hsp70 keeps the CFTR soluble until the E3 ligase 
CHIP binds with the Hsp70. The Hsp70-CHIP complex then redirects the CFTR to the 
degradation pathway. Within the ER membrane, Derlin-1 seems to be the main factor detecting 
mutations. Derlin-1 also seems to participate in the retro-translocation of CFTR from the ER so 
that it can be sent to the 26S proteasome for degradation [20]. ERAD within cells is an extremely 
complicated process that requires numerous factors and proteins that all interact with each other 
in complex pathways. This stringent system makes it nearly impossible for imperfect CFTR 
channels to make it to the membrane even if they could still function. However, without this 
system, our cells would be in danger of destruction from the aggregation of misfolded proteins.  
 If the CFTR protein is folded correctly within the ER, it is sent to the Golgi. This 
relocation requires the coat protein complex II (COPII) found within the ER membrane. The 
COPII helps to maintain the correct CFTR structure and location, conformation, and protein-
protein interactions. Once within the Golgi, the final processing for the CFTR is carried out 
where the CFTR replaces a mannose-enriched side chain with a mature complex oligosaccharide 
side chain. When the CFTR is fully mature, it is moved from the Golgi to the apical membrane 
via clathrin-coated vesicles. After CFTR is situated in the plasma membrane, it has a half-life of 
about 12 to 24 hours. The CFTR is then internalized by clathrin-coated endosomes. Another 
quality control system exists to detect poorly functioning CFTR within the membrane. The 
CFTR is first recognized by Hsc70 which leads to ubiquitylation. The protein is then internalized 
into an endosome and either sent back to the plasma membrane or degraded within a lysosome 
[16].  
CFTR Mutations 
 Over a thousand different mutations of the CFTR gene have been discovered that can 
lead to the cystic fibrosis phenotype. These mutations have been found in various locations such 
as the coding sequence for CFTR and the mRNA splice signals. The different mutations have 
been sorted into different classes based on the mechanism through which they lead to the disease 
state [21]. Mutations caused by deletions, frameshifts, and nonsense mutations that lead to a 
prematurely truncated CFTR are grouped into the class I mutations. Class II mutations generate 
proteins that are unable to pass through the intracellular trafficking process, even though many 
would be able function to some extent if they reached the plasma membrane. Class III mutations 
generate full length proteins that exhibit little or no channel activity once they reach the 
membrane due to disordered regulation. Class IV mutations result in proteins with slightly 
reduced channel function, and therefore create a less severe phenotype of cystic fibrosis. Class V 
mutant proteins are fully functional but are expressed within cells at a reduced level, and class VI 
mutants are expressed at a normal level but seem to be less stable within the plasma membrane. 
Mutant classes I, II, and III lead to the most severe phenotypes because there is little or no 
channel activity associated with these mutations [20].  
 The most common CFTR mutation is the ∆F508 which accounts for 90% of all the 
mutant CFTR alleles. It is also responsible for two thirds of diagnosed CF cases [22]. The ∆F508 
mutation results from the deletion of a phenylalanine at position 508. It was found that cells with 
the ∆F508 failed to produce fully glycosylated CFTR proteins; the CFTR is not fully processed 
and is degraded by the UPS before reaching the apical membrane. Therefore, the ∆F508 
mutation is classified as a class II mutant [23]. A small amount of ∆F508 CFTR proteins are able 
to bypass the ERAD system and reach the membrane, however the proteins are unstable and 
function poorly due to endocytosis and degradation by the UPS [5]. The ∆F508 CFTR has also 
been discovered to be temperature-sensitive. At lower temperatures, ∆F508 CFTR starts to act 
more like wild-type CFTR, with channels reaching the membrane and functioning correctly [24].  
 The ∆F508 mutation occurs within the NBD1 of CFTR. It has been found that the 
backbone structure and thermodynamic stability of ∆F508 CFTR are similar to those of wild 
type CFTR [25]. However, the ∆F508 mutation may cause both kinetic and thermodynamic 
folding defects within the NBD1. During the folding process, CFTR employs a cooperative 
folding mechanism. This implies that the folding energetics of the wild type NBD1 is stabilized 
by coupled domain folding, but this coupled domain folding is impaired in the ∆F508 NBD1. 
Due to this impairment, the assembly of the interface between NBD1 and both of the MSDs is 
also impaired, which destabilizes the conformations of the MSD1, MSD2, and NMD2 [26]. The 
incorrectly folded NBD2 acts as one of the signals targeting the CFTR for degradation and 
therefore accounts in part for the failure of ∆F508 CFTR to reach the apical membrane and 
function properly [22].  
 Another common mutation is the G542X, which is the second most common CFTR 
mutation. The G542X mutation is a nonsense mutation, and therefore categorized as a class I 
mutation [27]. Although the G542X mutation is more common in frequency than the G551D 
mutation (see below), it is not as widely discussed. 
 The third most common CF mutation is the G551D, which is found in the population at a 
frequency of about three percent. The G551D mutation causes a severe phenotype and is 
classified as a class III mutation. This mutation is caused by the glycine residue at position 551 
being replaced by an aspartate residue. This amino acid replacement causes a large reduction in 
CFTR channel activity. Similar to the ∆F508 mutation, G551D is located within the NBD1. 
Little is currently known about the mechanism that causes decreased channel activity within 
G551D CFTR. The G551D CFTR exhibits normal synthesis, trafficking, and processing. The R 
domain in this mutation can also be phosphorylated normally, but the channel still remains 
inactive. It was discovered that the on rate of channel activation by cAMP is greatly reduced, 
while the closed time of the CFTR channel increases. The G551D CFTR mutant has no channel 
response to either ATP or ADP [28]. The G551D mutation has become popular recently due to a 
breakthrough treatment that I will discuss later in this paper. 
 These two mutations are just a sample of the numerous mutations responsible for CF. 
Currently, approximately 1500 different mutations in the CFTR have been discovered that are 
capable of causing the disease phenotype. Compared to the ∆F508 mutation, these other 
mutations are extremely rare and not widely discussed [8]. Currently, only 22 mutations have 
been classified that occur with a frequency of over 0.1%. The other mutations are typically only 
seen in one or a few individuals [29].  
Primary Complications with CF 
 Cystic Fibrosis causes multiple health complications. The primary effect of CF is within 
the airways and submucosal glands [29]. CFTR is expressed throughout the lungs where it helps 
to maintain the proper chloride levels. However, with mutant CFTR, the chloride levels are not 
able to be regulated properly. This leads to an increase in intracellular chloride levels and a 
decrease in extracellular chloride levels. The chloride imbalance causes excess movement of 
water into the airway epithelial cells, which leads to extreme dehydration of the mucus layer 
coating the airway surface. The resulting thick mucus is difficult to dislodge and obstructs proper 
airflow, which impairs lung function capabilities. This thickened mucus also acts as a perfect 
environment for bacterial infections. Due to the complications that can arise from thick mucus 
within the lungs, dehydration of the airway surface is typically considered the initiating event in 
lung disease within CF patients [30].  
 Within a healthy lung, the mucus is mostly composed of mucin glycoproteins that can 
either be secreted by the cell or tethered onto the membrane of the cell. Two of the most 
important mucins, MUC5AC and MUC5B, appear to be greatly reduced in CF patients. As 
mentioned earlier, the main cause for this thick mucus is the decreased available extracellular 
water. However, there also seems to be a secondary cause of viscous mucus within the lungs: an 
increase in anionic polyelectrolytes, including DNA made from the invading bacteria and DNA 
released from lysed inflammatory cells. Thick mucus is also partly a result of an increase in actin 
molecules. Regardless of what causes this viscous mucus, it eventually builds up in the CF 
patients’ airways and detaches from the cilia. This in turn inhibits the mucociliary transport, 
which is the main cause of lung morbidity and ultimately mortality in CF patients [30]. 
 As mentioned before, the thick mucus lining the CF airways provides a perfect home for 
various bacterial infections. Shortly after birth, initial infection occurs from bacterial pathogens. 
The decreased function of the mucociliary transport prevents the clearing of the lungs. The 
antimicrobial peptides located in the airways become overwhelmed, allowing infections to take 
hold. Due to these infections, the CF airway shows a prolonged primary inflammatory response 
typical of a chronic infection. The manifestation of lung disease within CF patients is variable. 
Most individuals do not show symptoms while they are newborns, but signs of lung disease such 
as wheezing, coughing, and difficulty breathing can be seen in infants around six months of age. 
As an individual ages, coughing becomes a daily occurrence, usually accompanied by sputum. 
During later stages of the disease, it is not uncommon to find blood-streaked sputum [29].  
 A wide range of microorganisms are associated with pulmonary infections in CF patients. 
Infants and young children are most likely to be infected with Staphylococcus aureus and 
Haemophilus influenzae. Within older children and adults, Pseudomonas aeruginosa is more 
likely to be found within the airways [31]. H. influenzae is the most common microorganism 
found in the lower airways at age one. It is also non-typeable which means that the childhood 
immunization against H. influenzae type b has no affect in helping to prevent this infection. 
Currently, the role of this microorganism in the progressive pulmonary infection and 
inflammation in CF affected patients has not yet been clearly demonstrated, though it has been 
proven to be pathogenic in non-CF patients [29].  
 P. aeruginosa is the most significant microorganism associated with CF. Approximately 
80 percent of CF patients will eventually be infected by this pathogen, resulting in clinical 
deterioration. The source of P. aeruginosa is currently unknown, but the fact that most CF 
patients contain different genotypes of the bacteria suggests the infection comes from the 
environment [29]. Typically, chronic infection does not occur at first. Instead, there is a period of 
recurrent, intermittent colonization by the pathogen until the patient eventually develops a 
chronic infection. This normally occurs during the late twenties or early thirties in patients. In a 
chronic infection, there is a continuous growth of P. aeruginosa that leads to an increase in 
inflammation. This inflammation along with damage done by the bacteria itself is a major cause 
of damaged lung tissue and a decrease in lung function [32].  
 S. aureus is the most common pathogen found in CF children from ages 11 to 15 years. 
In the past ten years, S. aureus has gained a lot of attention due to the rise of methicillin resistant 
S. aureus (MRSA). Once MRSA has established itself within the CF airways, it is almost 
impossible to remove through antimicrobial therapy. Since 1960, approximately 80 percent of S. 
aureus has been resistant to penicillin, and within 2 years of the introduction of methicillin in 
1959, methicillin resistant strains began to develop. Initially, MRSA was only seen in hospitals, 
but the prevalence of MRSA within CF patients has increased from 2 percent in 2001 to 22.6 
percent in 2008 [33].  
 Following the development of MRSA, studies have investigated how MRSA affects CF 
patients in comparison to methicillin sensitive S. aureus (MSSA). It was found that CF patients 
infected with MRSA as the primary pathogen have lower lung function than those infected by 
MSSA. Patients with MRSA also show a higher rate of hospitalization and use of antibiotics 
[34]. MRSA CF patients also exhibit a faster decline in lung function than those without MRSA. 
Currently, treatment for MRSA has no guidelines but typically includes several different 
antibiotics used to help control the MRSA infection. There have also been some rare cases of 
eradication of MRSA in CF patients which is encouraging, in that MRSA might be able to be 
eradicated by the use of systematic antibiotic therapy [33].  
 Another resilient pathogen has also made its way into the CF community within recent 
years. This devastating bacterium is the Burkholderia cepacia complex (BCC). It can be found in 
multiple environments, including agricultural crops and aqueous solutions such as detergent 
solutions and intravenous fluids commonly found in hospitals. BCC was not a prominent 
pathogen within CF until recently, because patients had a shorter life expectancy. Now that 
patients with CF are living longer, BCC has been able to take hold and can be found in about ten 
percent of adult CF patients. A pulmonary infection of BCC can persist for months or even years. 
BCC can lead to severe disease or death within as little as six months. However, every individual 
reacts to BCC differently, with some patients not even experiencing a decline in clinical status 
after infection [35].  
 Managing CF patients infected with BCC leads to a serious problem because BCC is 
resistant to most antimicrobials and no new antibiotics have been produced that can kill this 
pathogen. BCC might be susceptible to some antimicrobials, but once it encounters a new 
antibiotic, it quickly develops a resistance. This leaves doctors with the problem of trying to treat 
a patient with a pathogen that is resistant to all known antimicrobials. There have been some 
reports of successful treatment of BCC in CF patients, but these reports are rare. The fact that CF 
individuals can become infected with BCC from the environment or from other fellow patients 
has led to great anxiety amongst the CF community. Infection control procedures were soon put 
in place to help prevent the spread of BCC. CF summer camps were shut down and patients with 
BCC were segregated from all other CF individuals. BCC infected individuals are no longer 
allowed to go to any CF gatherings such as fundraisers, and CF patients in general are told to 
keep their distance from each other in order to help prevent any unintentional spreading of BCC 
[35].  
 Another major complication found with CF is within the digestive system. Similar to the 
lungs, patients with CF have a coating of thick mucus within their intestines. Defective CFTR 
proteins within the digestive system causes impaired intestinal fluid secretion because the water 
moves into cells that are filled with chloride that cannot escape. This in turn leads to constipation 
and mucus filled stool. As mentioned earlier, constipation caused by CF helps to prevent death 
by Cholera, which is a leading theory for why CF is so prevalent [36]. The thick mucus in the 
digestive tract can also block pancreatic secretion of digestive enzymes that aid in the digestion 
and absorption of food. A blocked pancreas in CF patients can lead to pancreas insufficiency, 
malabsorption of fats and proteins, and a possible deficiency in fat-soluble vitamins [37].  
 A third major complication within CF adults is infertility. Approximately 98 percent of 
CF males are infertile. This infertility is caused by various different problems within the male 
reproductive system. Ultimately, almost all CF males are azoospermic, meaning that they do not 
have a measurable amount of sperm within their semen. Male CF patients typically have bilateral 
absence of the vans deferens. The body and tail of the epididymides are deformed or absent. The 
testes may or may not be reduced in size, and the seminal vesicles typically contain various 
abnormalities. It has been proposed that these abnormalities are caused by a failure of 
differentiation during the first trimester [38].  
 Female CF patients on the other hand do not have any reproductive system abnormalities. 
However, women with CF sometimes have a hard time getting pregnant due to the blockage of 
the cervix by mucus. Patients who decide to have a child must carefully plan out their pregnancy. 
Women must weigh issues such as a loss of lung function during pregnancy and the toxicity of 
certain drugs to the fetus. Typically women regain their lost lung function after giving birth, but 
some women fail to regain their lung function and die as a result. Therefore, it is imperative that 
CF patients talk to their doctors and make the best decision for their individual case as to 
whether they should become pregnant [38].  
Secondary Complications with CF 
 Along with the primary complications caused by CF, many patients experience secondary 
complications or comorbidities. One of the most severe secondary complications found with CF 
is diabetes. CF diabetes is a separate entity from type 1 and type 2 diabetes and is known as 
cystic fibrosis-related diabetes (CFRD).  CFRD is normally found within CF patients who have 
more severe forms of the disease, and is associated with an insufficient pancreatic exocrine 
function. CFRD leads to an insulin deficient state typically without ketoacidosis. The traditional 
model for the onset of CFRD is the “collateral damage” model. According to this model, thick 
mucus resulting from defective CFTR proteins leads to blockage and damage of the pancreas. 
Soon progressive fibrosis and fatty infiltration takes place, leading to the destruction of the 
hormone producing areas of the pancreas. Therefore, less insulin is produced and released into 
the blood stream [39]. 
 As healthy individuals age, it is normal for β-cell function to decline, leading to 
decreased insulin production. This natural decline along with β-cell abnormalities associated 
with CF, has led to an increase in CFRD as CF patients survive to an older age. CF patients with 
CFRD have a six fold greater mortality rate than those patients without diabetes. CFRD is also 
associated with lower lung function in CF patients. The decline in lung function can begin 
several years before the patient is diagnosed with CFRD. Another early sign of CFRD is a 
decrease in BMI. Although CFRD is a severe complication associated with CF, improvements in 
survival have been seen with early diagnosis and treatment. Therefore, now that CFRD is more 
common and better understood, doctors can screen their patients to catch the onset of diabetes as 
early as possible, greatly increasing the patient’s chance of survival [39].  
 Another secondary complication associated with CF is osteoporosis. However, in order to 
prevent any confusion with osteoporosis found in patients without CF, CF osteoporosis will be 
referred to as bone disease. Low bone mineral density (BMD) was first noted in CF patients in 
1979 [40]. Since low BMD is already common in the elderly population, the fact that CF patients 
are living longer has led to an increasing importance of understanding causes behind bone 
disease in CF patients. Within the CF population, fractures occurring due to bone disease 
typically are located within the vertebrae. It has also been noted that fracture incidents are more 
frequent in the female CF population. These fractures not only cause pain, but they can also 
prevent effective treatment of the lung disease associated with CF. Many treatments for CF lung 
disease induce coughing and methods to break up mucus within the lungs, and a fracture within 
the spinal cord would make these types of treatments impossible [41].  
 Currently, the mechanisms behind bone disease within CF patients are not completely 
understood. However, many risk factors for low BMD have been identified. The first risk factor 
is insufficient pancreatic activity. As mentioned earlier, this leads to malabsorption of nutrients 
therefore leading to malnutrition and a lower BMI. Both poor nutrition and low BMI are known 
to contribute to lower BMD values. Another issue with poor nutrition is decreased calcium 
absorption that is not reversed through the use of supplemental digestive enzymes. The second 
risk factor for bone disease in CF patients is vitamin D and vitamin K deficiencies. Both of these 
vitamins are important for the maintenance of bone structure. Due to poor pancreatic activity, 
these vitamins are not absorbed well, plus patients with CF typically do not take part in outdoor 
physical activities leading to an even greater vitamin D deficiency. A third factor is limited 
physical activity within CF patients. Bone mass increases with exercise due to force placed on 
the bone. However, since CF patients are normally not active, their bones do not have the proper 
pressure to strengthen. Bone disease in CF patients can also be caused by recurrent infections 
that lead to the reabsorption of bone. Also, glucocorticoids are typically used for CF patients to 
improve lung function, but these medications are known to decrease BMD. Finally, it has 
recently been discovered that the defective CFTR might lead to the dysregulation of genes 
important for bone formation [40].  
 CFRD and bone disease are just two of the many different secondary complications 
associated with CF. Another common complication is the development of pancreatitis. As 
mentioned earlier, mucus plugs the pancreas and leads to a decline in its function. If the pancreas 
becomes completely blocked, this can lead to pancreatitis. It has also been found that as CF 
patients are reaching older ages, their risk for gastrointestinal and pancreatic cancers is higher 
than average [42]. Other secondary complications can include pain such as chest pain and 
headaches. This pain not only reduces the patient’s quality of life, it also might interfere with a 
patient’s treatments. CF can also lead to complex social interactions where individuals struggle 
to explain CF to colleagues and friends. Serious psychiatric disorders are also associated with 
CF. Rates for both major depression and suicide are higher for adult individuals suffering from 
CF. This list of complications is still just a short overview of the myriad of complications that 
can be brought on by CF [43].  
Current Treatments 
 Many treatments for CF have been discovered over the years. These treatments typically 
treat the symptoms of CF and differ from patient to patient. One of the most common treatments 
today is hypertonic saline which is inhaled by patients through breathing treatments. The use of 
hypertonic saline in adults with CF has been proven to improve mucociliary clearance. 
Hypertonic saline works through two separate mechanisms. First, it targets the dehydration effect 
of CF within the lungs. By breathing in saline solution, water is drawn out of the cells within the 
lungs helping to loosen the thick mucus caused by defective CFTR proteins. Second, hypertonic 
saline induces coughing within patients. These coughing spells improve mucociliary clearance 
by creating a sheer force that promotes the removal of mucus within the airways. The increase in 
mucociliary clearance leads to better lung function within CF patients [30].  
 Another common inhaled treatment for CF is pulmozyme or dornase alfa. Pulmozyme 
was approved in 1994 for use in the treatment of CF [44]. This treatment contains an enzyme 
known as deoxyribonuclease I (DNase I). DNase I cleaves DNA, which can reduce the viscosity 
of mucus within CF patients. Due to chronic inflammation within CF lungs, there is an excess of 
cellular debris. This debris in turn increases the viscosity of the surrounding mucus. Therefore, 
pulmozyme works to reduce viscosity by digesting the extracellular DNA accumulated within 
the lungs. Similar to hypertonic saline, the loosening of mucus by pulmozyme allows for better 
clearance of the lungs. This leads to an increase in lung function and a decrease in respiratory 
exacerbations. Pulmozyme is also well tolerated in patients, making it an ideal treatment for 
those with CF [45].  
 Other treatments for CF include different types of chest physiotherapy. The oldest of 
these methods is conventional chest physiotherapy, which was introduced in the 1950s. This 
treatment involves pounding on the back of the patient in a head-down position which helps to 
slow the progression of declining respiratory function. Currently this treatment is only used in 
children due to side effects such as abnormal cardiac rhythms in adults. In the 1970s, another 
chest physiotherapy method was introduced called the PEP mask or more commonly the flutter. 
The flutter requires the patient to exhale through a mouthpiece that generates resistance. This 
resistance creates positive pressure within the airways, forcing air into the more distal lung 
regions in order to break up thick mucus secretions. The PEP mask has been found to be just as 
effective or more effective than the conventional chest physiotherapy method [46].  
 One of the most effective chest physiotherapy methods is high-frequency chest 
compression. This has been shown to increase mucociliary clearance by increasing expiration 
and creating forces leading to coughing. Eventually, a device was created called the Vest Airway 
Clearance System. The Vest works by applying high-frequency oscillations to the patient’s chest 
via an air-pulse-generating compressor. These oscillations help to move mucus secretions in the 
small airways into larger airways where they are more easily removed by coughing. This 
treatment is normally well tolerated, but in some patients with more advanced lung disease, it 
can cause pain and discomfort. Overall, the Vest is a good alternative for the conventional chest 
physiotherapy method and has been shown to decrease the rate of decline in pulmonary function 
over a long period of use [46].  
 Another main focus of CF treatment is controlling pulmonary infections. During early 
lung disease within CF patients, doctors typically prescribe antibiotics to help delay the chronic 
colonization of pathogens. Once pathogens have colonized, chronic maintenance antibiotics are 
given to patients to help slow the decline in pulmonary function. During times of increased 
pulmonary symptoms, patients are typically prescribed a more intense antibiotic regimen. 
Typically, these intense treatments are carried out through intravenous methods whether they be 
at a hospital or at home. Less intense antibiotic regimens are typically inhaled during a patient’s 
regular treatment times. Since there are a wide variety of bacterial infections that can take hold in 
CF patients’ lungs, there are also a large amount of antibiotics. Antibiotic treatments are 
individualized for each patient. There is no clear cut treatment plan for infections within CF 
patients [29].  
 In order to treat pancreatic insufficiency in CF patients, individuals are typically advised 
to alter their diet and consume supplemental pancreatic enzymes. To help prevent stomach 
issues, patients are advised to reduce their fat intake. It is also advised to reduce the intake of 
hard to digest foods. Along with a modified diet, patients take pancreatic enzymes to aid the 
digestion of fat and the absorption of some nutrients. Since enzymes in healthy individuals are 
typically released parallel to eating a meal, supplemental enzymes usually are taken at the same 
time as a snack or meal. These pancreatic enzymes not only help in digestion and absorption of 
nutrients, they also help in reducing stool frequency and improving stool consistency in CF 
patients. Execution of this therapy should be based on an individual level depending on each 
patient’s nutritional status and pancreatic damage [47].  
 The above treatments are just a few of a wide range of options for CF patients. Along 
with these treatments, doctors typically advise patients to follow an exercise regimen. Exercise 
has been proven to have a therapeutic effect on CF individuals [48]. Another possible treatment 
for CF is a lung transplant. This is a rescue therapy used in both adults and children who have 
terminal lung disease. The first lung transplantation for a CF patient occurred in 1983. There are 
many complications that occur during a lung transplantation, but if all goes well, a transplant can 
have dramatic results on a CF patient [49]. All of these treatments depend on each individual 
patient, and only a doctor and the patient can decide what treatment route is the best fit for their 
unique situation.  
 
Latest Breakthrough Therapies 
 The latest breakthrough for the treatment of CF is Vx-770 more commonly known as 
Kalydeco. Vx-770 was released in 2012 and is the first FDA-approved drug that directly affects 
the CFTR [50]. In the trial stages for Vx-770, it was found to have the greatest effect on CFTR 
proteins with the G551D mutation. A study was carried out that tested the safety and 
effectiveness in CF patients with at least one G551D allele. In the study, it was found that 
patients given Vx-770 showed significant improvements in lung function. CFTR function in 
nasal epithelial cells and sweat glands also showed improvement. During the study, there were a 
few adverse effects noted, but these were uncommon and relatively minor. It was determined that 
Vx-770 could be a viable therapeutic treatment for CF patients with the G551D mutation [51]. 
Although Vx-770 has already been approved, the exact mechanism by which the therapy works 
is not understood. Vx-770 is a CFTR potentiator and increases the open time of the CFTR 
channel. The binding site of Vx-770 is also unknown at this time. Unfortunately, this therapeutic 
treatment is only applicable to those with the G551D mutation, which only accounts for about 
three percent of the CF population. It has also been shown that Vx-770 is not a cure for G551D 
patients, but it offers a significant increase in patients’ health and provides hope for all those 
with or involved with CF [50]. 
 Other therapies are now making their way through the trial phases for the treatment of 
patients with the ∆F508 mutation. One of these therapies is Vx-809 combined with Vx-770. This 
therapy recently passed the second phase of study and is now in the works of a phase three study. 
Vx-809 is known as a CFTR corrector, and it helps the CFTR protein reach the cell membrane. 
The Vx-770 then works as a potentiator to help keep the CFTR channel open for longer periods 
of time. In the phase two trial, there was a significant increase in lung function for patients taking 
the combination of Vx-809 and Vx-770. The combination of treatments also appears to be well 
tolerated with patients, with the most severe side effects being pulmonary in nature. Soon the 
phase three trial will be conducted for Vx-809 and Vx-770, providing hope for individuals with 
the most common CF mutation [52].  
 Another breakthrough therapy undergoing trials for the ∆F508 mutation is the 
combination of Vx-661 and Vx-770. This combination therapy just recently finished its phase 
two study. Like Vx-809, Vx-661 is a CFTR corrector used to help move the ∆F508 mutated 
CFTR to the apical membrane. This combination therapy also seems to be well tolerated by 
patients, with only some mild to moderate pulmonary side effects. The study showed significant 
decreases in sweat chloride production, which is unusually high in patients with CF. With high 
enough doses, Vx-661 and Vx-770 together led to a significant increase in lung function. Along 
with Vx-809 and Vx-661, there is still another potential corrector for CFTR being tested. 
However, of these three correctors, Vx-809 is currently the leader, providing the greatest hope 
for a radical treatment for those with the ∆F508 mutation [53].  
 Currently, there is another potential therapy moving through the trial stages called 
ataluren. This therapy is effective for patients who have a nonsense mutation in their CFTR gene. 
Ataluren is a drug that allows for ribosomal readthrough of mRNA molecules that contain 
premature stop codons. It was determined that ataluren leads to the proper translation of a CFTR 
protein. Although the trial period was short, there were trends towards higher lung function and a 
decrease in coughing. These results prove that there could be a clinical benefit of ataluren in 
individuals with a nonsense mutation in their CFTR gene. Further research is needed to access 
the improvement in lung function before this drug will be ready for release to the general CF 
population. Although it has not been released yet, this is another possible therapy for individuals 
suffering from CF [54].  
Conclusion  
 Cystic Fibrosis is a terrible disease that still has no cure. However, progress since the 
discovery of CF in 1938 has come in leaps and bounds. CF patients have gone from not living 
beyond childhood to a life expectancy well into adulthood. Scientists have a better understanding 
of the causes of CF and therefore can now focus more attention on developing treatments. Over 
the past few years, new radical prospective therapies have been making their way through trials. 
The release of Kalydeco was a monumental moment for the CF community. Hopefully, Vx-809 
soon will be released along with Vx-770 to greatly increase the quality and length of life for 
those with the ∆F508 mutation. No matter what happens in the future, there is no doubt that the 
outlook on CF has changed dramatically over the years. At the rate that discoveries are being 
made in the CF community, I have no doubt that within the near future, CF patients will be able 
to live healthy, normal lives with the help of amazing new therapies.  
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